Effect of different doses of aspirin on the prognosis of Kawasaki disease

Table 1 Demographic characteristics

Group	1	2	3	P-value
N	510	1487	372
Weight (kg)	11.50 (10.50–15.45)	11.30 (9.00–14.00)	10.50 (7.50–13.00)	<0.001
Age (month)	22.14 (14.83–39.93)	19.43 (10.66–35.14)	15.79 (6.45–29.30)	<0.001
IVIG treat time (day)	6.00 (6.00–8.00)	6.00 (6.00–7.00)	6.00 (6.00–7.00)	0.574
SEX				0.574
Male	337 (66.08%)	948 (63.75%)	244 (65.59%)
Female	173 (33.92%)	539 (36.25%)	128 (34.41%)
IVIG treat option				0.004
No use	27 (5.29%)	46 (3.09%)	5 (1.34%)
1 g or 2 g options	483 (94.71%)	1441 (96.91%)	367 (98.66%)

Data are shown as number (N), mean (SD), or median (Q1–Q3)/N (%)
IVIG: intravenous immunoglobulin
Group 1: patients with Kawasaki disease treated with aspirin at 20–30 mg/kg/d in the acute stage
Group 2: patients with Kawasaki disease treated with aspirin at 30–40 mg/kg/d in the acute stage
Group 3: patients with Kawasaki disease treated with aspirin at 40–50 mg/kg/d in the acute stage

ISSN: 1546-0096